Transcatheter aortic valve implantation (TAVI) is the primary therapeutic option for severe aortic stenosis that are inoperable or have high surgical risk.
Diffusion-weighted MRI studies demonstrates that after TAVI some silent embolic cerebral infarcts are present that lead to consecutive mental deterioration. Cerebral embolic protection (CEP) devices is used to reduce the risk of stroke, neurocognitive decline and dementia caused by brain emboli associated with cardiovascular procedures.

The global Cerebral Thrombectomy Systems market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Cerebral Thrombectomy Systems volume and value at global level, regional level and company level. From a global perspective, this report represents overall Cerebral Thrombectomy Systems market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Cerebral Thrombectomy Systems in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Cerebral Thrombectomy Systems manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Terumo
ohnson and Johnson
Stryker
Vascular Solutions
Boston Scientific
Medtronic
Teleflex
Penumbra
The Spectranetics Corporation
AngioDynamics

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Clarets Sentinel System
Keystone Hearts Triguard Device
Embrella Embolic Deflector

Segment by Application
Hospital
Clinic